Press "Enter" to skip to content

Alexion Pharmaceutical Inc. Increased to Outperform

The Shares of Alexion Pharmaceuticals Inc. inched 0.84% higher to $169.91 Wednesday. This proved to be an all-around favourable trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to 4,167.59 and the Dow Jones Industrial Average DJIA rising 0.29% to 34,230.34.

Alexion Pharmaceuticals Inc. closed $2.17 short of its 52-week high ($172.08), which the company achieved on April 30th. The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Gilead Sciences Inc. GILD rose 1.33% to $66.51, Vertex Pharmaceuticals Inc. VRTX fell 0.46% to $213.87, and Regeneron Pharmaceuticals Inc. REGN fell 0.57% to $482.42. Trading volume (1.7 M) remained 782,415 below its 50-day average volume of 2.4 M.

Alexion Pharmaceuticals Inc. was upgraded by research analysts at Oppenheimer from a market perform rating to an outperform rating in a research note issued to investors on Wednesday. The firm currently has a $205.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price target indicates a potential upside of 21.67% from the stock’s previous close. They issued a “neutral” rating and a $190.00 price objective on the stock.

The stock opened at $168.49 on Wednesday. The company has a current ratio of 3.81, a quick ratio of 3.26 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $37.22 billion, a P/E ratio of 39.37, a PEG ratio of 0.75 and a beta of 1.33. The business has a 50 day simple moving average of $158.33 and a 200-day simple moving average of $146.37. The Pharmaceuticals has a twelve month low of $94.82 and a twelve month high of $172.08

Be First to Comment

Leave a Reply

Your email address will not be published.